Page last updated: 2024-11-11

2,8-dimethyl-3-methylene-1-oxa-8-azaspiro(4,5)decane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,8-dimethyl-3-methylene-1-oxa-8-azaspiro(4,5)decane: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6918122
SCHEMBL ID5000310
MeSH IDM0185646

Synonyms (8)

Synonym
bdbm81495
ym796(-)
132041-81-7
SCHEMBL5000310
(-)-(s)-2,8-dimethyl-3-methylene-1-oxa-8-azaspiro[4.5]decane
(-)-(s)-2,8-dimethyl-3-methylene-1-oxa-8azaspiro[4.5]decane
HDTOQYUZMCNTBZ-JTQLQIEISA-N
2,8-dimethyl-3-methylene-1-oxa-8-azaspiro(4,5)decane

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The bioavailability after oral administration of (S)-(-)-2,8-dimethyl-3-methylene-1-oxa-8-azaspiro [4,5] decane-L-tartarate monohydrate (YM796), which is being developed as an antidementia drug, at a dose of 1 mg/kg was very low (3."( Prediction of species differences (rats, dogs, humans) in the in vivo metabolic clearance of YM796 by the liver from in vitro data.
Iwatsubo, T; Sugiyama, Y; Suzuki, H, 1997
)
0.3
" These results suggest that it is possible to predict Fh even if the metabolism is composed of non-linear process by considering the absorption rate into the portal vein."( Prediction of in vivo nonlinear first-pass hepatic metabolism of YM796 from in vitro metabolic data.
Hisaka, A; Iwatsubo, T; Sugiyama, Y; Suzuki, H, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's14 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.74 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]